BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 9, 2023
Product Development

Catalysts beyond cystic fibrosis await Vertex after $8.9B year

Along with its successor to blockbuster Trikafta in CF, the biotech is advancing a diversified pipeline encompassing pain, hematology and kidney disease
BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

U.K. biotech sells one ion channel program, keeps another
BioCentury | Sep 13, 2019
Company News

Vertex reaches CF deal in Scotland

BioCentury | Aug 22, 2019
Politics & Policy

Changing of the guard at NICE

BioCentury | Aug 12, 2019
Company News

Vertex fails to reach CF deal in Scotland

BioCentury | Jun 26, 2019
Politics & Policy

NICE RWE proposal could open door to more managed access

Items per page:
1 - 10 of 89
Help Center
Username
Request Training
Submit Data Correction
Ask a Question